Category Archives: Prostate Cell

Prostate Cell News is an online publication and email newsletter summarizing the latest prostate cell research.
Subscribe
Published every week since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.

FRMD6 has Tumor Suppressor Functions in Prostate Cancer

In overexpression and CRISPR/Cas9 knockout experiments in prostate cancer cell lines, FRMD6 inhibited viability, proliferation, cell cycle progression, colony formation, 3D spheroid growth, and tumor xenograft growth in mice.
[Oncogene]
Haldrup, J., Strand, S. H., Cieza-Borrella, C., Jakobsson, M. E., Riedel, M., Norgaard, M., Hedensted, S., Dagnaes-Hansen, F., Ulhoi, B. P., Eeles, R., Borre, M., Olsen, J. V., Thomsen, M., Kote-Jarai, Z., & Sorensen, K. D. (2020). FRMD6 has tumor suppressor functions in prostate cancer. Oncogene, 1–14. https://doi.org/10.1038/s41388-020-01548-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent rhPSMA-7.3 (18F) in Collaboration with Nucleis Radiopharmaceuticals in Liege, Belgium

Blue Earth Diagnostics’ manufacturing partner, Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
[Blue Earth Diagnostics]
Press Release
Bookmark

No account yet? Register

0
Share

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer

The authors expand on the clinical development of PARP inhibitors (PARPis) in metastatic castration-resistant prostate cancer, discuss potential biomarkers that may predict successful tumor control, and summarize present and future clinical research on PARPis in the metastatic disease landscape.
[Cancers]
Jang, A., Sartor, O., Barata, P. C., & Paller, C. J. (2020). Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Cancers, 12(11), 3467. https://doi.org/10.3390/cancers12113467 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Progression-Free Survival of Prostate Cancer Patients Is Prolonged with a Higher Regucalcin Expression in the Tumor Tissues: Overexpressed Regucalcin Suppresses the Growth and Bone Activity in Human Prostate Cancer Cells

Overexpression of regucalcin in bone metastatic human prostate cancer PC-3 and DU-145 cells suppressed colony formation and cell growth in vitro. Overexpressed regucalcin enhanced the levels of p53, Rb, and p21, and decreased the levels of Ras, PI3 kinase, Akt, and mitogen-activated protein kinase, leading to suppression of cell growth.
[Translational Oncology]
Yamaguchi, M., Osuka, S., Murata, T., & Ramos, J. W. (2021). Progression-free survival of prostate cancer patients is prolonged with a higher regucalcin expression in the tumor tissues: Overexpressed regucalcin suppresses the growth and bone activity in human prostate cancer cells. Translational Oncology, 14(1), 100955. https://doi.org/10.1016/j.tranon.2020.100955 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target

Scientists demonstrated that inhibiting the P2X4 receptor impaired the growth and mobility of prostate cancer cells but not apoptosis. In BALB/c immunocompromised nude mice inoculated with human PC3 cells subcutaneously, 5-BDBD showed anti-tumourigenic effects.
[Cells]
He, J., Zhou, Y., Arredondo Carrera, H. M., Sprules, A., Neagu, R., Zarkesh, S. A., Eaton, C., Luo, J., Gartland, A., & Wang, N. (2020). Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target. Cells, 9(11), 2511. https://doi.org/10.3390/cells9112511 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

18F-Fluciclovine PET Metabolic Imaging Reveals Prostate Cancer Tumor Heterogeneity Associated with Disease Resistance to Androgen Deprivation Therapy

Isogenic androgen-responsive and castration-resistant human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts.
[EJNMMI Research]
Malviya, G., Patel, R., Salji, M., Martinez, R. S., Repiscak, P., Mui, E., Champion, S., Mrowinska, A., Johnson, E., AlRasheedi, M., Pimlott, S., Lewis, D., & Leung, H. Y. (2020). 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Research, 10(1), 143. https://doi.org/10.1186/s13550-020-00728-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer

Investigators evaluated the potential effect of protein disulfide isomerase 4 on chemoresistance to docetaxel (DTX) in prostate cancer cells (DTX-resistant PC-3 cells and C4-2B cells) to investigate the underlying mechanisms.
[Chemotherapy]
Qian, S., Zhang, S., Wu, Y., Ding, Y., Shen, H., & Li, X. (2020). Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer. Chemotherapy, 1–9. https://doi.org/10.1159/000511505 Cite
Abstract
Bookmark

No account yet? Register

0
Share

In Vitro-Transcribed Antigen Receptor mRNA Nanocarriers for Transient Expression in Circulating T Cells In Vivo

In mouse models of human leukemia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated infusions of these polymer nanocarriers induced sufficient host T cells expressing tumor-specific CARs or virus-specific TCRs to cause disease regression at levels similar to bolus infusions of ex vivo engineered lymphocytes.
[Nature Communications]
Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S., & Stephan, M. T. (2020). In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nature Communications, 11(1), 6080. https://doi.org/10.1038/s41467-020-19486-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

miR-199b-5p-DDR1-ERK Signaling Axis Suppresses Prostate Cancer Metastasis via Inhibiting Epithelial-Mesenchymal Transition

Investigators demonstrated that miR-199b-5p was significantly downregulated in metastatic prostate cancer (PCa) tissues and cells when compared with the normal prostate tissue, the localized disease, the weakly metastatic and androgen-dependent PCa cell and the normal prostate epithelial cell.
[British Journal of Cancer]
Zhao, Z., Zhao, S., Luo, L., Xiang, Q., Zhu, Z., Wang, J., Liu, Y., & Luo, J. (2020). miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition. British Journal of Cancer, 1–13. https://doi.org/10.1038/s41416-020-01187-8 Cite
Abstract
Bookmark

No account yet? Register

0
Share

microRNA-211-Mediated Targeting of the INHBA-TGF-β Axis Suppresses Prostate Tumor Formation and Growth

Scientists indicated that upregulation of miR-211 has tumor-suppressive properties by inhibiting TGF-β pathway activation via INHBA in prostate cancer stem cells.
[Cancer Gene Therapy]
Zhao, Z., Wang, K., & Tan, S. (2020). microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth. Cancer Gene Therapy, 1–15. https://doi.org/10.1038/s41417-020-00237-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

Identification of Transcription Factor Co-Regulators that Drive Prostate Cancer Progression

Researchers demonstrated an approach to identify cancer-driver coregulators in cancer, and that PGC1α expression is clinically significant yet underexplored coregulator in aggressive early stage prostate cancer.
[Scientific Reports]
Identification of transcription factor co-regulators that drive prostate cancer progression | Scientific Reports. (n.d.). Retrieved November 24, 2020, from https://www.nature.com/articles/s41598-020-77055-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share